{"id":7880,"date":"2025-10-26T23:02:21","date_gmt":"2025-10-26T23:02:21","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/10\/26\/novartis-acquire-avidity-rna-neuromuscular-diseases\/"},"modified":"2025-10-26T23:02:21","modified_gmt":"2025-10-26T23:02:21","slug":"novartis-acquire-avidity-rna-neuromuscular-diseases","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/10\/26\/novartis-acquire-avidity-rna-neuromuscular-diseases\/","title":{"rendered":"STAT+: Novartis to buy RNA-focused Avidity in $12 billion deal"},"content":{"rendered":"<p>    STAT+: Novartis to buy RNA-focused Avidity in $12 billion deal<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p>LONDON \u2014 Novartis said Sunday it would buy Avidity Biosciences, which is developing RNA-based therapies for neuromuscular diseases, for roughly $12 billion in cash.\u00a0<\/p>\n<p>The deal, at $72 a share, represents a 46% premium on Avidity\u2019s closing share price on Friday of $49.15.\u00a0<\/p>\n<p>With the purchase, Novartis is picking up three late-stage programs: one treatment for Duchenne muscular dystrophy, another for myotonic dystrophy type 1, and <a href=\"https:\/\/www.statnews.com\/2024\/06\/12\/avidity-biosciences-fshd-muscular-dystrophy\/\">a third for facioscapulohumeral muscular dystrophy<\/a>.\u00a0Novartis said it could see product launches from the acquisition before 2030.\u00a0<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/10\/26\/novartis-acquire-avidity-rna-neuromuscular-diseases\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Andrew Joseph<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/10\/26\/novartis-acquire-avidity-rna-neuromuscular-diseases\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: Novartis to buy RNA-focused Avidity in $12 billion deal LONDON \u2014 Novartis said Sunday it would buy Avidity Biosciences, which is developing RNA-based therapies for neuromuscular diseases, for roughly $12 billion in cash.\u00a0 The deal, at $72 a share, represents a 46% premium on Avidity\u2019s closing share price on Friday of $49.15.\u00a0 With the [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2194,2154,2208,2155,2152],"tags":[2150],"class_list":["post-7880","post","type-post","status-publish","format-standard","hentry","category-biotech","category-biotechnology","category-drug-development","category-pharmaceuticals","category-stat","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/7880"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=7880"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/7880\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=7880"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=7880"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=7880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}